These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 2968808)

  • 21. Principles and mechanisms of receptor studies.
    Herzog H
    Nuklearmedizin; 1990 Mar; 29(2):81. PubMed ID: 2339088
    [No Abstract]   [Full Text] [Related]  

  • 22. [Review of the system of positron emission tomography and its clinical application].
    Tateno Y; Shishido F
    No To Shinkei; 1982 Sep; 34(9):827-43. PubMed ID: 6215930
    [No Abstract]   [Full Text] [Related]  

  • 23. Positron emission tomographic scan investigations of Huntington's disease: cerebral metabolic correlates of cognitive function.
    Berent S; Giordani B; Lehtinen S; Markel D; Penney JB; Buchtel HA; Starosta-Rubinstein S; Hichwa R; Young AB
    Ann Neurol; 1988 Jun; 23(6):541-6. PubMed ID: 2970247
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PET scan investigations of Huntington's disease: cerebral metabolic correlates of neurological features and functional decline.
    Young AB; Penney JB; Starosta-Rubinstein S; Markel DS; Berent S; Giordani B; Ehrenkaufer R; Jewett D; Hichwa R
    Ann Neurol; 1986 Sep; 20(3):296-303. PubMed ID: 2945510
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dopamine receptor classification, neuroanatomical distribution and in vivo imaging.
    Brücke T; Wenger S; Podreka I; Asenbaum S
    Wien Klin Wochenschr; 1991; 103(21):639-46. PubMed ID: 1771898
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early-onset Huntington's chorea. Diagnostic clues.
    Brooks DS; Murphy D; Janota I; Lishman WA
    Br J Psychiatry; 1987 Dec; 151():850-2. PubMed ID: 2971414
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Positron emission tomography studies of dopamine D1 receptors].
    Shinotoh H
    Nihon Rinsho; 1991 Jul; 49(7):1541-5. PubMed ID: 1832196
    [No Abstract]   [Full Text] [Related]  

  • 28. Brain energy metabolism and dopaminergic function in Huntington's disease measured in vivo using positron emission tomography.
    Leenders KL; Frackowiak RS; Quinn N; Marsden CD
    Mov Disord; 1986; 1(1):69-77. PubMed ID: 2973559
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Where have we got to with neuroreceptor mapping of the human brain?
    Mazière B; Mazière M
    Eur J Nucl Med; 1990; 16(11):817-35. PubMed ID: 2170141
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aspects of PET imaging relevant to the assessment of striatal transplantation in Huntington's disease.
    Besret L; Kendall AL; Dunnett SB
    J Anat; 2000 May; 196 ( Pt 4)(Pt 4):597-607. PubMed ID: 10923990
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of two PET radioligands for imaging extrastriatal dopamine receptors in the human brain.
    Wang GJ; Volkow ND; Fowler JS; Wolf AP; MacGregor RR; Shea CE; Schlyer DJ; Hitzemann RJ
    Synapse; 1993 Nov; 15(3):246-9. PubMed ID: 8278901
    [No Abstract]   [Full Text] [Related]  

  • 32. Comparison of somatosensory evoked potentials with striatal glucose consumption measured by positron emission tomography in the early diagnosis of Huntington's disease.
    Kuwert T; Noth J; Scholz D; Schwarz M; Lange HW; Töpper R; Herzog H; Aulich A; Feinendegen LE
    Mov Disord; 1993; 8(1):98-106. PubMed ID: 8419813
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Positron emission tomography of brain dopamine D-1 receptors with 11C-SCH 23390 in Parkinson's disease.
    Rinne JO; Laihinen A; Någren K; Bergman J; Haaparanta M; Solin O; Ruotsalainen U; Rinne UK
    Acta Radiol Suppl; 1991; 376():152. PubMed ID: 1666760
    [No Abstract]   [Full Text] [Related]  

  • 34. Single photon emission computed tomography in subjects at risk for Huntington's chorea.
    Leblhuber F; Brucker B; Reisecker F; Steinparz F; Windhager E; Trenkler J; Deisenhammer E
    J Neurol; 1990 Dec; 237(8):496-8. PubMed ID: 2150077
    [No Abstract]   [Full Text] [Related]  

  • 35. Iodine-123-IBZM dopamine D2 receptor and technetium-99m-HMPAO brain perfusion SPECT in the evaluation of patients with and subjects at risk for Huntington's disease.
    Ichise M; Toyama H; Fornazzari L; Ballinger JR; Kirsh JC
    J Nucl Med; 1993 Aug; 34(8):1274-81. PubMed ID: 8326384
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human brain receptor distribution.
    Frey KA; Agranoff BW; Young AB; Hichwa RD; Ehrenkaufer RL
    Science; 1986 Jun; 232(4755):1269-71. PubMed ID: 3704652
    [No Abstract]   [Full Text] [Related]  

  • 37. No deficit of pallidal D2 dopamine receptors in Huntington's disease.
    Reynolds GP; Brown JE; Pearson SJ
    J Neurol Sci; 1990 Dec; 100(1-2):238-9. PubMed ID: 2150971
    [No Abstract]   [Full Text] [Related]  

  • 38. Positron emission tomography of brain dopamine D-2 receptors with 11C-raclopride in early Parkinson's disease.
    Laihinen A; Rinne JO; Någren K; Bergman J; Haaparanta M; Solin O; Ruotsalainen U; Rinne UK
    Acta Radiol Suppl; 1991; 376():151. PubMed ID: 1666759
    [No Abstract]   [Full Text] [Related]  

  • 39. Single photon emission computed tomography in Huntington's chorea.
    Leblhuber F; Hoell K; Reisecker F; Gebetsberger B; Puehringer W; Trenkler E; Deisenhammer E
    Psychiatry Res; 1989 Sep; 29(3):337-9. PubMed ID: 2532751
    [No Abstract]   [Full Text] [Related]  

  • 40. Non-invasive in vivo imaging of transplant function.
    Brooks DJ; Piccini P
    Prog Brain Res; 2000; 127():321-32. PubMed ID: 11142033
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.